Status:

COMPLETED

Mannitol-induced Release of Copeptin in Healthy Adults and Patients With Polyuria-Polydipsia Syndrome (MARS Study)

Lead Sponsor:

University Hospital, Basel, Switzerland

Conditions:

Polyuria-polydipsia Syndrome

Arginine Vasopressin Deficiency

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The aims of this study are to investigate whether mannitol stimulates copeptin (part 1: proof-of-concept) and whether the copeptin levels upon mannitol infusion differ in primary polydipsia and argini...

Detailed Description

Diagnosing polyuria-polydipsia syndrome, which includes arginine vasopressin (AVP) deficiency (AVP-D, formerly central diabetes insipidus) and primary polydipsia (PP), is challenging but essential. Cu...

Eligibility Criteria

Inclusion

  • Part 1: Proof of Concept in Healthy adults
  • Age ≥ 18 years
  • Healthy with no medication except hormonal contraception
  • Part 2: Pilot Study in Patients with primary polydipsia (PP) or arginine vasopressin deficiency (AVP-D)
  • Age ≥ 18 years
  • Evidence of polyuria \> 40-50 ml/kg body weight per 24 hours and polydipsia \> 3 Liter per 24 hours or regular desmopressin medication corresponding to a diagnosis of PP or AVP-D

Exclusion

  • Part 1: Proof of Concept in Healthy adults
  • Participation in a trial with investigational drugs within 30 days
  • Evidence of disordered drinking habits and diuresis defined as polyuria \> 40-50 ml/kg body weight per 24 hours and polydipsia \> 3 Liter per 24 hours.
  • Estimated Glomerular Filtration Rate (eGFR) \< 60 ml/min/1,73 m2
  • Glucose \> 11.1 mmol/L corresponding to the diagnosis of an uncontrolled diabetes mellitus
  • History of urinary tract obstruction
  • Problems with urination
  • Pregnancy or breastfeeding
  • Multiple allergies (≥ 3)
  • Evidence of acute illness
  • Part 2: Pilot Study in Patients with PP or AVP-D
  • Participation in a trial with investigational drugs within 30 days
  • Pregnancy or breastfeeding
  • Evidence of acute illness
  • eGFR \< 60 ml/min/1,73 m2
  • Glucose \> 11.1 mmol/L corresponding to the diagnosis of uncontrolled diabetes mellitus
  • History of urinary tract obstruction
  • Problems with urination
  • Therapy with diuretics
  • Multiple allergies (≥ 3)

Key Trial Info

Start Date :

September 10 2024

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 22 2025

Estimated Enrollment :

42 Patients enrolled

Trial Details

Trial ID

NCT06542198

Start Date

September 10 2024

End Date

July 22 2025

Last Update

December 15 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Hospital Basel

Basel, Switzerland, 4031